Dyskinesia – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Dyskinesia – Drugs In Development, 2024 report and make more profitable business decisions.
Dyskinesia refers to the involuntary nature of muscular movements or the difficulty in performing voluntary muscular movement. Symptoms include facial grimacing, finger movement, jaw swinging, repetitive chewing, and tongue thrusting. The disease can be controlled by healthy life style and medication.
The Dyskinesia drugs in development market research report provide comprehensive information on the therapeutics under development for Dyskinesia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Dyskinesia | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 80 molecules, with 75 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Dyskinesia therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Dyskinesia pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Dyskinesia treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AbbVie IncAddex Therapeutics Ltd
Adeptio Pharmaceuticals Ltd
Adhera Therapeutics Inc
AEON Biopharma Inc
AfaSci Inc
Astraea Therapeutics LLC
Bod Science Ltd
Celon Pharma SA
Cerevel Therapeutics Holdings Inc
ConSynance Therapeutics Inc
Contera Pharma ApS
Daewoong Pharmaceutical Co Ltd
DanPET AB
Domain Therapeutics SA
Drexel University
EpiVax Inc
ES Therapeutics LLC
GABA Therapeutics Inc
Gerbera Therapeutics Ltd
GraySpace Therapeutics Inc
Hua Medicine Shanghai Ltd
IRLAB Therapeutics AB
Jazz Pharmaceuticals Plc
Junaxo Inc
Luye Pharma Group Ltd
MapLight therapeutics Inc
Merz Pharma GmbH & Co KgaA
Michigan State University
Microgen
MitoDys Therapeutics Ltd
Mitsubishi Tanabe Pharma Corp
Molomics Biotech SL
Motac Neuroscience Ltd
Neuralina Therapeutics Inc
Neurim Pharmaceuticals Ltd
Neurocrine Biosciences Inc
Neurolixis Inc
Nissan Chemical Corp
Novartis AG
OB Pharmaceuticals
Omeros Corp
Peptron Inc
PharmaTher Holdings Ltd
PolyCore Therapeutics LLC
Praxis Precision Medicines Inc
Puretech Health Plc
Sage Therapeutics Inc
Shanghai Fosun Pharmaceutical (Group) Co Ltd
Shionogi & Co Ltd
Sinopia Biosciences Inc
SOM Biotech SL
Sumitomo Pharma Co Ltd
Tempero Bio
Teva Pharmaceutical Industries Ltd
Trevi Therapeutics Inc
University of California San Diego
University of Montreal
Vanderbilt University
Viatris Inc
VistaGen Therapeutics Inc
Zambon Co SpA
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Dyskinesia reports